Huntington's disease: CoQ10 being investigated in trial to prevent deterioration.
This article was originally published in The Tan Sheet
Executive Summary
HUNTINGTON's DISEASE CLINICAL TRIAL WITH COENZYME Q10 will examine the ability of the dietary supplement and a drug regimen to prevent deterioration of motor skills associated with the fatal inherited disorder. Other symptoms of the progressive genetic disease include problems with coordination, cognitive difficulties and depression. Along with CoQ10, the study will evaluate Astra Merck's experimental drug remacemide. Patients will be randomized to CoQ10, remacemide, both or placebo for 30 months.